Iván Márquez‐Rodas

29.0k total citations · 3 hit papers
120 papers, 4.1k citations indexed

About

Iván Márquez‐Rodas is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Iván Márquez‐Rodas has authored 120 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 83 papers in Oncology, 52 papers in Molecular Biology and 19 papers in Immunology. Recurrent topics in Iván Márquez‐Rodas's work include Cancer Immunotherapy and Biomarkers (42 papers), CAR-T cell therapy research (38 papers) and Melanoma and MAPK Pathways (37 papers). Iván Márquez‐Rodas is often cited by papers focused on Cancer Immunotherapy and Biomarkers (42 papers), CAR-T cell therapy research (38 papers) and Melanoma and MAPK Pathways (37 papers). Iván Márquez‐Rodas collaborates with scholars based in Spain, United States and United Kingdom. Iván Márquez‐Rodas's co-authors include Vanna Chiarion‐Sileni, Dirk Schadendorf, James Larkin, David Hogg, Michael Smylie, Piotr Rutkowski, F. Stephen Hodi, Reinhard Dummer, René González and Jedd D. Wolchok and has published in prestigious journals such as Nature, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Iván Márquez‐Rodas

110 papers receiving 4.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

2018 1.0k citations F. Stephen Hodi, Vanna Chiarion‐Sileni et al. profile →
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial

2017 482 citations Jean‐Jacques Grob, Ana Arance et al. profile →
Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy

2019 323 citations María E. Rodríguez-Ruiz, José Luis Perez‐Gracia et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Iván Márquez‐Rodas Spain	25	3.0k	1.3k	1.2k	778	380	120	4.1k
Luis de la Cruz‐Merino Spain	26	2.6k 0.9×	1.9k 1.4×	812 0.7×	703 0.9×	541 1.4×	175	4.0k
Geoffrey T. Gibney United States	32	4.0k 1.3×	2.0k 1.5×	1.8k 1.4×	1.3k 1.7×	583 1.5×	123	5.8k
Shunchang Jiao China	30	1.9k 0.6×	1.1k 0.8×	618 0.5×	977 1.3×	655 1.7×	144	3.4k
Tobias Janowitz United States	22	2.0k 0.7×	1.0k 0.7×	1.1k 0.9×	816 1.0×	574 1.5×	53	3.6k
Michele Guida Italy	27	2.2k 0.7×	1.2k 0.9×	892 0.7×	691 0.9×	350 0.9×	146	3.2k
Romualdo Barroso‐Sousa Brazil	25	2.4k 0.8×	800 0.6×	764 0.6×	818 1.1×	672 1.8×	95	3.8k
Andreas Pircher Austria	27	1.5k 0.5×	1.7k 1.2×	871 0.7×	855 1.1×	931 2.5×	103	3.4k
Vasiliki Pelekanou United States	30	1.8k 0.6×	720 0.5×	838 0.7×	768 1.0×	607 1.6×	75	3.0k
Robert Wesolowski United States	29	1.5k 0.5×	724 0.5×	789 0.6×	551 0.7×	354 0.9×	176	2.7k
Lev Demidov Russia	26	3.7k 1.2×	3.4k 2.5×	1.2k 1.0×	632 0.8×	464 1.2×	141	5.3k

Countries citing papers authored by Iván Márquez‐Rodas

Since Specialization

Citations

This map shows the geographic impact of Iván Márquez‐Rodas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Iván Márquez‐Rodas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Iván Márquez‐Rodas more than expected).

Fields of papers citing papers by Iván Márquez‐Rodas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Iván Márquez‐Rodas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Iván Márquez‐Rodas. The network helps show where Iván Márquez‐Rodas may publish in the future.

Co-authorship network of co-authors of Iván Márquez‐Rodas

This figure shows the co-authorship network connecting the top 25 collaborators of Iván Márquez‐Rodas. A scholar is included among the top collaborators of Iván Márquez‐Rodas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Iván Márquez‐Rodas. Iván Márquez‐Rodas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ascierto, Paolo A., Michele Del Vecchio, Barbara Merelli, et al.. (2025). 1609P Final, 9-year results from the CheckMate 238 phase III trial of adjuvant nivolumab vs ipilimumab in resected stage IIIB–C or IV melanoma. Annals of Oncology. 36. S887–S888.

Muñoz‐Couselo, Eva, L. A. Fernández, Miguel‐Ángel Berciano‐Guerrero, et al.. (2025). Retreatment and rechallenge with BRAF/MEK inhibitors in patients with metastatic melanoma: results from the real-world Spanish Melanoma Registry (GEM-1801). Clinical & Translational Oncology. 28(1). 320–329.

Donia, Marco, Henrik Jespersen, Mathilde Jalving, et al.. (2025). Adjuvant immunotherapy in the modern management of resectable melanoma: current status and outlook to 2028. ESMO Open. 10(3). 104295–104295. 2 indexed citations

González‐Cao, María, Teresa Puértolas, José Luís Zamora Manzano, et al.. (2024). Access to melanoma drugs in Spain: a cross-sectional survey. Clinical & Translational Oncology. 26(10). 2572–2583. 3 indexed citations

García‐Martínez, Elena, et al.. (2024). Chemokine profiling of melanoma–macrophage crosstalk identifies CCL8 and CCL15 as prognostic factors in cutaneous melanoma. The Journal of Pathology. 262(4). 495–504. 9 indexed citations

González‐Cao, María, Teresa Puértolas, José Luís Zamora Manzano, et al.. (2024). Access to systemic treatment of non-melanoma skin cancer in Spain: a survey analysis. Clinical & Translational Oncology. 27(1). 386–391. 1 indexed citations

Márquez‐Rodas, Iván, et al.. (2024). SEOM-GEM clinical guidelines for cutaneous melanoma (2023). Clinical & Translational Oncology. 26(11). 2841–2855.

Larkin, John O., Piotr Rutkowski, Christopher D. Lao, et al.. (2024). LBA43 10-y survival outcomes from the phase III CheckMate 067 trial of nivolumab plus ipilimumab in advanced melanoma. Annals of Oncology. 35. S1234–S1235. 2 indexed citations

Rodon, Jordi, Filip De Vos, M. De Miguel, et al.. (2024). 1081MO Phase I study of WNT974 in combination with spartalizumab in patients with cutaneous melanoma. Annals of Oncology. 35. S716–S717. 1 indexed citations

10.

Hodi, F. Stephen, Vanna Chiarion‐Sileni, René González, et al.. (2023). Durable clinical outcomes in patients (pts) with advanced melanoma and progression-free survival (PFS) ≥3y on nivolumab (NIVO) ± ipilimumab (IPI) or IPI in checkmate 067.. Journal of Clinical Oncology. 41(16_suppl). 9542–9542.

11.

Zatarain‐Nicolás, Eduardo, Pilar Martı́n, Iván Márquez‐Rodas, et al.. (2023). Cardiovascular toxicity of checkpoint inhibitors: review of associated toxicity and design of the Spanish Immunotherapy Registry of Cardiovascular Toxicity. Clinical & Translational Oncology. 25(11). 3073–3085. 4 indexed citations

12.

Calles, Antonio, et al.. (2023). Unleashing a Lazarus Effect With Selpercatinib in a Never-Smoker Patient With Stage IV, Chemo-Immunotherapy Refractory, RET C630Y-Mutant, Small-Cell Lung Cancer: A First Case Report. JCO Precision Oncology. 7(7). e2300321–e2300321. 1 indexed citations

13.

Márquez‐Rodas, Iván, Luigi Formisano, Sophie Papa, et al.. (2022). Understanding the Lived Experiences of Patients With Melanoma: Real-World Evidence Generated Through a European Social Media Listening Analysis. JMIR Cancer. 8(2). e35930–e35930. 5 indexed citations

14.

Martín, Andrés J. Muñoz, et al.. (2021). Venous thromboembolism incidence in cancer patients with germline BRCA mutations. Clinical & Translational Oncology. 24(1). 154–158. 1 indexed citations

15.

García‐Martínez, Elena, María Eugenia Fernández‐Santos, Amaya Puig‐Kröger, et al.. (2021). CCL20/TNF/VEGFA Cytokine Secretory Phenotype of Tumor-Associated Macrophages Is a Negative Prognostic Factor in Cutaneous Melanoma. Cancers. 13(16). 3943–3943. 16 indexed citations

16.

Márquez‐Rodas, Iván, et al.. (2019). Utility of PET/CT in patients with stage I–III melanoma. Clinical & Translational Oncology. 22(8). 1414–1417. 7 indexed citations

17.

Aznar, M. Ángela, Lourdes Planelles, Carmen Molina, et al.. (2019). Immunotherapeutic effects of intratumoral nanoplexed poly I:C. Journal for ImmunoTherapy of Cancer. 7(1). 116–116. 103 indexed citations

18.

Márquez‐Rodas, Iván, et al.. (2019). A retrospective chart review study describing metastatic melanoma patients profile and treatment patterns in Spain. Clinical & Translational Oncology. 21(12). 1754–1762. 1 indexed citations

19.

Samaniego, Rafael, Alejandra Gutiérrez‐González, Iván Márquez‐Rodas, et al.. (2018). CCL20 Expression by Tumor-Associated Macrophages Predicts Progression of Human Primary Cutaneous Melanoma. Cancer Immunology Research. 6(3). 267–275. 62 indexed citations

20.

Mandalà, Mario, M. Del Vecchio, Helen Gogas, et al.. (2018). Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Updated results from a phase 3 trial (CheckMate 238). British Journal of Cancer. 119(11). 41–42. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact